Published in Women's Health Weekly, December 23rd, 2010
"It is unclear whether the effects of the progesterone agent 17-alpha-hydroxyprogesterone caproate (17P) are additive in women with both primary risk factors. It is also unclear whether 17P is beneficial for women with a prior SPTB and a short CL not undergoing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.